← Leaderboards
M Eileen Dolan
University Of Chicago
$15,055,139
Attributed
$18,790,656
Total exposure
18
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,672,994 · 19
By mechanism
U01$13,216,651 · 5
T32$4,878,959 · 1
R01$3,538,322 · 2
R25$2,535,732 · 1
P50$1,903,166 · 2
R21$1,227,573 · 3
Top collaborators
- Mark J Ratain16 shared
- Nancy J. Cox6 shared
- Peter Hugh O'Donnell5 shared
- Lucy Ann Godley2 shared
- Rong Stephanie Huang2 shared
- Megan Mekinda2 shared
- Wei Zhang2 shared
- Michael L. Maitland1 shared
Most similar at University Of Chicago
Same institution · by research overlap
- Lucy Ann Godley$5,215,217
- Rong Stephanie Huang$4,360,763
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelBaseLaboratoriesMalignant NeoplasmsUniversitiesProgramsResourcesPharmaceutical PreparationsInnovationMedicineChicagoCell LineSamplingCytotoxicityCareer DevelopmentComprehensive Cancer CenterFacultyMentorsCareerClinical TrialsGenetic PolymorphismClinical ResearchDoctor Of PhilosophyAntineoplastic Agents
Grant awards (96)
Chicago EYES (Educators and Youth Enjoy Science) on Cancer {2024}$253,607
R25 · FY2025 · CA · contact PI
Chicago EYES (Educators and Youth Enjoy Science) on Cancer {2024}$310,524
R25 · FY2024 · CA · contact PI
Clinical Therapeutics$301,147
T32 · FY2024 · GM
Clinical Therapeutics$632,158
T32 · FY2023 · GM
Chicago EYES (Educators and Youth Enjoy Science) on Cancer$150,000
R25 · FY2023 · CA · contact PI
Clinical Therapeutics$615,118
T32 · FY2022 · GM · contact PI
Chicago EYES (Educators and Youth Enjoy Science) on Cancer$342,518
R25 · FY2022 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$75,413
P30 · FY2022 · CA · contact PI
Clinical and Experimental Therapeutics$36,824
P30 · FY2022 · CA · contact PI
Clinical Therapeutics$586,974
T32 · FY2021 · GM · contact PI
Chicago EYES (Educators and Youth Enjoy Science) on Cancer$364,207
R25 · FY2021 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$75,851
P30 · FY2021 · CA · contact PI
Clinical and Experimental Therapeutics$37,040
P30 · FY2021 · CA · contact PI
Clinical Therapeutics$555,779
T32 · FY2020 · GM · contact PI
Modeling Vincristine-Induced Severe and Persistent Neuropathy$176,175
R21 · FY2020 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$75,851
P30 · FY2020 · CA · contact PI
Clinical and Experimental Therapeutics$37,040
P30 · FY2020 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$4,736
P30 · FY2020 · CA · contact PI
Clinical and Experimental Therapeutics$4,735
P30 · FY2020 · CA · contact PI
Chicago EYES (Educators and Youth Enjoy Science) on Cancer$340,118
R25 · FY2019 · CA · contact PI
Clinical Therapeutics$315,158
T32 · FY2019 · GM
Modeling Vincristine-Induced Severe and Persistent Neuropathy$211,410
R21 · FY2019 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$75,851
P30 · FY2019 · CA · contact PI
Clinical and Experimental Therapeutics$37,040
P30 · FY2019 · CA · contact PI
Clinical Therapeutics$529,850
T32 · FY2018 · GM
Chicago EYES (Educators and Youth Enjoy Science) on Cancer$366,151
R25 · FY2018 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$75,353
P30 · FY2018 · CA · contact PI
Clinical and Experimental Therapeutics$34,661
P30 · FY2018 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$2,728
P30 · FY2018 · CA · contact PI
Clinical and Experimental Therapeutics$2,727
P30 · FY2018 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$2,621
P30 · FY2018 · CA · contact PI
Clinical and Experimental Therapeutics$2,621
P30 · FY2018 · CA · contact PI
Clinical Therapeutics$508,721
T32 · FY2017 · GM
Chicago EYES (Educators and Youth Enjoy Science) on Cancer$408,607
R25 · FY2017 · CA · contact PI
Clinical Therapeutics$423,831
T32 · FY2016 · GM
Clinical Therapeutics$410,223
T32 · FY2015 · GM
PAAR-Pharmacogenomics of Anticancer Agents Research Group$1,849,572
U01 · FY2014 · GM
PAAR-Pharmacogenomics of Anticancer Agents Research Group$100,000
U01 · FY2014 · GM
CORE III - Lymphoblastoid Cell Line CORE (LCL)$50,846
U01 · FY2014 · GM · contact PI
PAAR-Pharmacogenomics of Anticancer Agents Research Group$1,826,851
U01 · FY2013 · GM
Genetic determinants associated with pemetrexed response and toxicity$299,756
R01 · FY2013 · CA · contact PI
CORE III - Lymphoblastoid Cell Line CORE (LCL)$51,255
U01 · FY2013 · GM · contact PI
PAAR-Pharmacogenomics of Anticancer Agents Research Group$1,979,869
U01 · FY2012 · GM
Genetic determinants associated with pemetrexed response and toxicity$318,890
R01 · FY2012 · CA · contact PI
Epigenetic and Genetic Dissection of Drug Response$211,858
R21 · FY2012 · HG
PHARMACOLOGY$118,759
P30 · FY2012 · CA · contact PI
CORE III - Lymphoblastoid Cell Line CORE (LCL)$53,633
U01 · FY2012 · GM · contact PI
PAAR-Pharmacogenomics of Anticancer Agents Research Group$2,022,046
U01 · FY2011 · GM
Genetic determinants associated with pemetrexed response and toxicity$318,890
R01 · FY2011 · CA · contact PI
Epigenetic and Genetic Dissection of Drug Response$250,610
R21 · FY2011 · HG
PHARMACOLOGY$124,535
P30 · FY2011 · CA · contact PI
CORE III - Lymphoblastoid Cell Line CORE (LCL)$54,159
U01 · FY2011 · GM · contact PI
PAAR-Pharmacogenomics of Anticancer Agents Research Group$2,104,000
U01 · FY2010 · GM
Identifying population specific variants important in toxicity to breast cancer C$330,570
P50 · FY2010 · CA · contact PI
Genetic determinants associated with pemetrexed response and toxicity$329,867
R01 · FY2010 · CA · contact PI
Incorporation of microRNA expression in pharmacogenetic prediction models$171,600
R21 · FY2010 · CA · contact PI
PHARMACOLOGY$135,611
P30 · FY2010 · CA · contact PI
CORE III - Lymphoblastoid Cell Line CORE (LCL)$74,315
U01 · FY2010 · GM · contact PI
Genetic determinants associated with pemetrexed response and toxicity$341,638
R01 · FY2009 · CA · contact PI
Identifying population specific variants important in toxicity to breast cancer C$330,483
P50 · FY2009 · CA · contact PI
Cellular Susceptibility$220,220
U01 · FY2009 · GM · contact PI
Incorporation of microRNA expression in pharmacogenetic prediction models$205,920
R21 · FY2009 · CA · contact PI
PHARMACOLOGY$133,465
P30 · FY2009 · CA · contact PI
Whole Genome$78,538
U01 · FY2009 · GM · contact PI
Identifying population specific variants important in toxicity to breast cancer C$322,057
P50 · FY2008 · CA · contact PI
Role of DNA In Protecting Against Secondary Leukemias$248,448
R01 · FY2008 · CA · contact PI
Cellular Susceptibility$223,791
U01 · FY2008 · GM · contact PI
PHARMACOLOGY$82,879
P30 · FY2008 · CA · contact PI
Whole Genome$79,819
U01 · FY2008 · GM · contact PI
Identifying population specific variants important in toxicity to breast cancer C$322,057
P50 · FY2007 · CA · contact PI
Role of DNA In Protecting Against Secondary Leukemias$248,806
R01 · FY2007 · CA · contact PI
Cellular Susceptibility$237,667
U01 · FY2007 · GM · contact PI
Whole Genome$84,763
U01 · FY2007 · GM · contact PI
Role of DNA In Protecting Against Secondary Leukemias$256,976
R01 · FY2006 · CA · contact PI
Cellular Susceptibility$255,820
U01 · FY2006 · GM · contact PI
Identifying population specific variants important in toxicity to breast cancer C$194,660
P50 · FY2006 · CA · contact PI
Whole Genome$76,680
U01 · FY2006 · GM · contact PI
Role of DNA In Protecting Against Secondary Leukemias$265,523
R01 · FY2005 · CA
Cellular Susceptibility$254,215
U01 · FY2005 · GM
Whole Genome$89,504
U01 · FY2005 · GM
Role of DNA In Protecting Against Secondary Leukemias$274,500
R01 · FY2004 · CA
HYDROLYSIS OF IRINOTECAN BY CARBOXYLESTERASES$362,272
U01 · FY2002 · GM
HYDROLYSIS OF IRINOTECAN BY CARBOXYLESTERASES$362,272
U01 · FY2002 · GM
DNA REPAIR IN PROTECTING AGAINST SECONDARY LEUKEMIAS$217,962
R01 · FY2002 · CA
CORE--PHARMACOLOGY$0
P30 · FY2002 · CA
CORE--PHARMACOLOGY$0
P30 · FY2002 · CA
HYDROLYSIS OF IRINOTECAN BY CARBOXYLESTERASES$362,272
U01 · FY2001 · GM
DNA REPAIR IN PROTECTING AGAINST SECONDARY LEUKEMIAS$211,616
R01 · FY2001 · CA
PHARMACOLOGY OF ANTICANCER AGENTS$103,677
P50 · FY2001 · DE
PHARMACOLOGY OF ANTICANCER AGENTS$103,677
P50 · FY2001 · DE
HYDROLYSIS OF IRINOTECAN BY CARBOXYLESTERASES$362,272
U01 · FY2000 · GM
DNA REPAIR IN PROTECTING AGAINST SECONDARY LEUKEMIAS$205,450
R01 · FY2000 · CA
PHARMACOLOGY OF ANTICANCER AGENTS$102,434
P50 · FY2000 · DE
CORE--IN VIVO TESTING OF AGT INHIBITORS$98,125
U19 · FY2000 · CA
METABOLIC STUDIES OF AGT INHIBITORS$98,125
U19 · FY2000 · CA
PHARMACOLOGY OF ANTICANCER AGENTS$93,551
P50 · FY2000 · DE